From Nasdaq: 2025-06-10 17:22:00

On Tuesday, Gilead Sciences (NASDAQ: GILD) saw its stock drop over 2% after the FDA ordered a halt to its testing of a two-drug combination to treat HIV due to low levels of CD4+ T-cells in some participants.

Despite the setback, Gilead has other HIV treatments in development unaffected by the FDA’s hold. With a wide pipeline of 58 investigational programs, the pause doesn’t seem like a major setback for the company.

While Gilead Sciences may face challenges in its HIV program, the Motley Fool Stock Advisor team has identified 10 other stocks for investors to consider for potential high returns.



Read more at Nasdaq: Why Gilead Scinces Stock Tumbled on Tuesday